M Maier1, V Valet, N Feucht, C P Lohmann. 1. Klinik und Poliklinik für Augenheilkunde, Klinikum rechts der Isar der Technischen Universität München, München, Deutschland. Mathias.Maier@mri.tum.de
Abstract
BACKGROUND: This article reports about the use of a combined photodynamic therapy (PDT) and intravitreal injection of bevacizumab as a treatment option in nine patients with chronic central serous chorioretinopathy (CSC). PATIENTS AND METHODS: A total of nine male patients with chronic CSC were treated with standard PDT laser treatment with verteporfin and intravitreal injection of bevacizumab administered within 24 h. Before and 1, 3, 6, 9 and 12 months after treatment the results of visual acuity, fluorescein angiography (FA) and optical coherence tomography (OCT) examinations were documented. RESULTS: All patients showed an improvement in visual acuity of 1-4 ETDRS lines. Mean visual acuity increased from baseline 20 / 40 to 20 / 25 after 3 months. FA and OCT findings showed a restitution of leakages and subretinal fluid in all cases. After 6-12 months follow-up 8 patients had ongoing improvement in vision without recurrence of CSC. CONCLUSION: The combination of PDT with bevacizumab in this case series appears to be an effective and safe therapy combination which is suitable as a therapeutic option for patients with chronic CCS without a tendency to recovery.
BACKGROUND: This article reports about the use of a combined photodynamic therapy (PDT) and intravitreal injection of bevacizumab as a treatment option in nine patients with chronic central serous chorioretinopathy (CSC). PATIENTS AND METHODS: A total of nine male patients with chronic CSC were treated with standard PDT laser treatment with verteporfin and intravitreal injection of bevacizumab administered within 24 h. Before and 1, 3, 6, 9 and 12 months after treatment the results of visual acuity, fluorescein angiography (FA) and optical coherence tomography (OCT) examinations were documented. RESULTS: All patients showed an improvement in visual acuity of 1-4 ETDRS lines. Mean visual acuity increased from baseline 20 / 40 to 20 / 25 after 3 months. FA and OCT findings showed a restitution of leakages and subretinal fluid in all cases. After 6-12 months follow-up 8 patients had ongoing improvement in vision without recurrence of CSC. CONCLUSION: The combination of PDT with bevacizumab in this case series appears to be an effective and safe therapy combination which is suitable as a therapeutic option for patients with chronic CCS without a tendency to recovery.
Authors: Michael D Ober; Lawrence A Yannuzzi; Diana V Do; Richard F Spaide; Neil M Bressler; Lee M Jampol; Allison Angelilli; Chiara M Eandi; Alice T Lyon Journal: Ophthalmology Date: 2005-12 Impact factor: 12.079